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Abstract
Purpose Sarcopenia is an age-related muscle condition
which is frequently a precursor of frailty, mobility dis-
ability and premature death. It has a high prevalence in
older populations and presents a considerable social and
economic burden. Potential treatments are under develop-
ment but, as yet, no guidelines support regulatory studies
for new drugs to manage sarcopenia. The objective of this
position paper is therefore to suggest a set of potential
endpoints and target population definitions to stimulate
debate and progress within the medico-scientific and reg-
ulatory communities.
Methods A multidisciplinary expert working group was
hosted by the European Society for Clinical and Economic
Aspects of Osteoporosis and Osteoarthritis, which
reviewed and discussed the recent literature from a per-
spective of clinical experience and guideline development.
Relevant parallels were drawn from the development of
definition of osteoporosis as a disease and clinical assess-
ment of pharmaceutical treatments for that indication.
Results A case-finding decision tree is briefly reviewed
with a discussion of recent prevalence estimations of dif-
ferent relevant threshold values. The selection criteria for
patients in regulatory studies are discussed according to the
aims of the investigation (sarcopenia prevention or
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treatment) and the stage of project development. The
possible endpoints of such studies are reviewed and a plea
is made for the establishment of a core outcome set to be
used in all clinical trials of sarcopenia.
Conclusions The current lack of guidelines for the
assessment of new therapeutic treatments for sarcopenia
could potentially hinder the delivery of effective medicines
to patients at risk.
Keywords Clinical trials  Sarcopenia  Public health 
Preventative health care  Frailty
Introduction
Sarcopenia is a syndrome characterised by progressive and
generalized loss of skeletal muscle mass and strength; it is
a major pathway leading to physical frailty [1]. Since, the
loss of muscle mass and strength is inherent in normal
ageing, the switch towards a pathological condition must
be established empirically, by the combination of diag-
nostic thresholds and associated risk of mobility-related
outcomes, poor quality of life and death [2–4]. Until
recently, there have been several different definitions of
sarcopenia; a situation which may have hindered the
development of regulatory and treatment guidelines. While
numerous research centres are trying to develop either
pharmaceutical agents, specific oral nutritional supple-
ments or specific exercise regimes to try to counteract
muscle decline [5], this lack of consensus on diagnosis, and
consequently guidelines, is likely to cause inefficiencies in
time and resources. To some extent, this situation
resembles that of the early 1990’s when companies were
trying to develop products for osteoporosis.
Following on from previous publications on the subject
of sarcopenia [6–8], this position paper describes the con-
clusions made during an expert working group meeting of
the European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO).
The theoretical definition of sarcopenia
In 2010, three separate expert panels [2–4] reached con-
sensus on similar statements defining sarcopenia as a
condition characterised by declining muscle mass and
function. In the words of the European Working Group on
Sarcopenia in Older People (EWGSOP), sarcopenia is a
condition ‘characterized by progressive and generalized
loss of skeletal muscle mass and strength, with a risk of
adverse outcomes such as physical disability, poor quality
of life and death’ [2]. A key feature of this definition is the
incorporation of low muscle strength (frequently referred
to as dynapenia), which is generally more strongly asso-
ciated with poor function and disability than low muscle
mass [9]. Primary sarcopenia is then the loss of muscle
mass and function that deviates negatively from normal
ageing in a progressive and chronic fashion and without
other obvious causal factors. Secondary sarcopenia may be
used to describe the loss of muscle mass and function when
causal factors other than (or in addition to) ageing are
involved. Other contributory factors might be inadequate
dietary intake of energy and/or protein (either due to
geriatric anorexia, malabsorption, gastrointestinal disor-
ders, or use of medications that cause anorexia). The onset
of sarcopenia secondary to a systemic disease (particularly
of an inflammatory, malignancy or endocrine nature or due
to advanced organ failure) is usually (but not always)
referred to as cachexia [2, 3]. Obese individuals with sar-
copenia are a subgroup with a particularly high risk of
adverse outcomes; the evidence suggests that the co-exis-
tence of these conditions creates a synergy in the risk of
developing multiple comorbidities [10, 11].
Regulatory insights from the field of osteoporosis
Sarcopenia and osteoporosis share many contributory (and
causative) factors. Both are consequences of biological
ageing and both are associated with higher risk of mobility
limitation, fractures and disability in the activities of daily
living [12]. Indeed ‘‘sarcopenia can be considered for
muscle, what osteoporosis is to bone’’ [13]. Thus, it might
be expected that there should be a number of parallels in
the development of the definitions of each these conditions
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and how this has led, in the case of osteoporosis, to the
development of regulatory and treatment guidelines.
Bijlsma and colleagues [14] identified a number of mile-
stones in the development of the recognition of osteo-
porosis as a disease, including: coining the term (in 1830),
the development of non-invasive imaging [dual-energy
X-ray absorptiometry (DXA)] (1987), the increasing
pharmaceutical interest (linked to the development of
putative anti-osteoporotic agents) and public awareness of
the increased fracture risk with age (1980’s), the concep-
tual definition (1990), the operational definition (1994) and
risk stratification (2008). It could be argued that for sar-
copenia, we are at the stage of pharmaceutical interest, but
before widespread public awareness; the crucial next step
will be agreement on an operational definition with
accepted thresholds of normal/abnormal muscle mass and
function, and how these vary by gender and ethnicity.
Both bone and skeletal muscle are in a state of dynamic
equilibrium; a constant process of breakdown and recon-
struction. Muscle mass can be increased by resistance
exercises, but if it is not optimally used it will be subse-
quently lost, since high muscle mass requires a relatively
greater maintenance energy expenditure. A major differ-
ence with bone is that muscle mass can be lost and rebuilt
fairly rapidly, at least in younger adults, but this ability to
rebuild muscle diminishes significantly in older individuals
[15]. Importantly, muscle constitutes an important reserve
of protein that can be called upon in periods of undernu-
trition [16].
After a peak and a plateau phase in tissue growth,
senescence steps in [17]; a process of biological ageing
resulting in the gradual deterioration of bone density,
muscle mass and strength. The loss in muscle mass is
shaped by the decline in the production of growth and
anabolic sex hormones, although the exact relationship
between hormone status and muscle function is complex
both in men and women [18, 19]. This contributes to the
declining muscle strength [20] but is not completely
explanatory [10, 21]. An important factor here is con-
comitant obesity [10, 22], since this will exacerbate the
drop in anabolic hormone production [23] and negatively
impact muscle quality [24], increasing the risk of sar-
copenia in both men and women [11, 25]. The decline in
muscle mass and strength in the majority of older indi-
viduals engenders no major hazard, but for some individ-
uals the decline is severe, leading to a downward spiral of
reduced mobility, frailty, increasing comorbidity risk and
premature death.
A conceptual definition of osteoporosis was finally
achieved at an international consensus conference held in
Hong Kong in March 1993 [26]. An international consen-
sus on a conceptual definition of sarcopenia still seems
hesitant; the newer definitions, which introduce the notions
of reduced mass, strength and function, are however
gaining ground.
Operational definitions
Osteoporosis
The definition of osteoporosis was operationalized in 1994
[27], as being bone mineral density (BMD) T-score
(measured using DXA) of -2.5 or lower (i.e. at least 2.5
standard deviations below average BMD of healthy young
individuals). This threshold provides an indicator that
defines individuals with a significantly greater fracture risk
than the population average [28]. A diagnosis of osteo-
porosis therefore indicates an elevated risk of fracture and
could lead to the prescription of an anti-osteoporotic agent.
The risk of fracture, however, depends also on other clin-
ical factors, such as prior fracture history, BMI, glucocor-
ticoid use, family history, etc. risk also varies markedly in
different countries. For these reasons, the decision whether
or not to prescribe an anti-osteoporotic agent is frequently
done using a risk algorithm (e.g. FRAX) with or without
the incorporation of a BMD value [29]. Thus, the original
biological marker, BMD, has lost some of its diagnostic
relevance to the risk algorithms.
Sarcopenia
Unlike the relatively straight-forward measurement of
BMD and its comparison to a reference, muscle mass can
be estimated by a variety of techniques and there are
numerous methods for adjusting the result for body size
and corpulence [7]. As a first step towards an operational
definition of sarcopenia, the EWGSOP group argued the
case for using three well-researched and measures of
muscle mass or function: gait speed, hand grip strength
(HGS) and appendicular lean mass (ALM); they also pro-
posed a set of thresholds (cut-points) for each that could be
indicative of a pathological condition.
More recently, the challenge was taken up by the
research team for the Foundation for the National Institutes
of Health (FNIH) Sarcopenia Project (FNIH-SP) which has
now published a set of thresholds based on an extensive
reanalysis of existing studies in sarcopenia [30]. Like the
EWGSOP, the FNIH-SP group considered that gait speed,
HGS and ALM are key measures of muscle mass and
function which can be used for a diagnosis of sarcopenia.
This group were of the opinion, however, that slow gait
speed (i.e. mobility impairment) is more of a primary
outcome of low muscle mass and strength and is not
(necessarily) part of the diagnostic process. The research
team used this ‘‘outcome’’ to determine threshold values
Aging Clin Exp Res (2016) 28:47–58 49
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for the two other criteria, first in cross-sectional analyses,
and then using the values obtained in a predictive manner
on the longitudinal data. The project pooled nine studies in
older, community dwelling, individuals (n = 26,625
assessable participants) having available data on HGS, gait
speed and body composition using DXA [30]. The average
age of the cohort was 75.2 (standard deviation: ±6.1) years
for men and 78.6 (±5.9) years for women, with a high
prevalence of obesity in both genders.
Diagnostic tests
Gait speed
The clinically relevant threshold for gait speed chosen by
the EWGSOP consensus and the FNIH-SP group was
0.8 m/s [2, 30]; below this level there is a strong associa-
tion with reduced survival and increased risk of disability
[31–34]. Both groups, and most other studies, have opted to
use the same cut-off for both men and women. It is clear
from various sources, however, that men walk faster than
women even at advanced ages [35, 36], suggesting that
having a single cut-off might overestimate the number of
women with low lower-body physical capacity and
underestimate the number of men. It is likely that different
thresholds may also have to be made for different ethnic
groups [37, 38].
Handgrip strength
The FNIH-SP analysis [39] identified two threshold values
each for men and for women; thus defining three strength
groups: low, intermediate and high. For men these values
were\26 and\32 kg (rounded to nearest whole value) and
for women were \16 and \20 kg. The proportions of
mobility disability observed in the three groups were, for
men: 40, 21 and 6 %; and for women: 51, 36 and 20 %,
respectively. The relevant low strength values of HGS
suggested by EWGSOP were\30 kg for men and\20 kg
for women.
It has previously been determined that body height is
positively correlated with muscle strength (even after
adjusting the dynamometer for hand size) and therefore
should be an adjustment factor (fat mass should also be
considered as an adjustment factor) [40]. The FNIH-SP
group examined the effect of including this and other
anthropomorphic factors in their classification and regres-
sion tree analyses to identify the most appropriate model
for the prediction of slow gait speed, including the ratio of
strength to body size (grip strength/height, grip strength/
height2, grip strength/weight, and grip strength/BMI); only
the adjustment by BMI appeared to have better predictive
value, and only in women [41]. For the men, statistically
significant interactions were observed for the adjustments
on height (a stronger association between weakness and
slow walking in taller men) and on age (a stronger asso-
ciation in the 65–79 year age group than in the 80? years
group). At present, the FNIH-SP group has advocated not
adjusting HGS on anthropomorphic criteria.
Appendicular lean mass
The FNIH-SP analysis [42] found that appendicular lean
mass (ALM; the sum of the lean mass of both arms and
both legs) was significantly and positively correlated with
grip strength in men and in women. Using the first level
thresholds of HGS as a definition of weakness (\26 and
\16 kg in men and women, respectively), the study found
an ALM threshold for men of \20 kg (rounded value),
below which the prevalence of weakness was 18 % and
above which was 2.5 %. For women, two ALM thresholds
were identified, one at\12 kg and another at\15 kg, but
for simplicity the lower of the two was ignored in further
analysis. The prevalence of weakness in women with
ALM\15 kg was 30 and 11 % if above this threshold.
Since, ALM varies according to body size, it is often
indexed to the square of body height and thresholds applied
by, for example, a rule of two standard deviations below a
reference population [43] (giving cut-offs of\5.5 kg/m2
for women and \7.25 kg/m2 for men as advocated by
EWGSOP). The FNIH-SP group tested various adjustments
on anthropomorphic variables in their analyses, including
ALM adjusted for height, or height squared, or weight, or
BMI, or total body fat; as well as leg lean mass (LLM)
adjusted for each of the above variables. Amongst these,
the strongest associations between the other measures of
muscle strength/performance were found when ALM was
adjusted for (divided by) BMI (ALMBMI). For men, the
ALMBMI threshold was \0.789 (giving a group with a
prevalence of weakness of 11.8 %); for women the
threshold was\0.512 (giving a group with a prevalence of
weakness of 31.0 %). In predictive analyses, these thresh-
olds were associated with higher odds of mobility impair-
ment for both men and women. ALMBMI was not as
strongly associated with incident mobility deficit as
weakness, but it did significantly predict incident mobility
impairment. This novel method of adjusting the measure-
ment of lean mass probably explains in large part the dif-
ferential rates of diagnosis of sarcopenia with respect to
EWGSOP criteria [44] and will need further confirmation.
Previous studies have shown that most of the inter-indi-
vidual variation in ALM in persons of a similar age can be
explained by height and weight (leaving aside gender and
racial differences), and after controlling for these, ALM
decreases with age by about 0.4 kg/decade in women and
50 Aging Clin Exp Res (2016) 28:47–58
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0.8 kg/decade in men [45]. It is clear, however, that fat
mass is very relevant to muscle quality [22, 46] and to the
decline in gait speed [36]. So it is somewhat unexpected
that the FNIH-SP researchers did not find any of the obe-
sity measures selected as primary discriminators of weak-
ness in the database and therefore abandoned obesity as
being explanatory.
Conclusions on proposed operational definitions
of sarcopenia
The FNIH-SP group studies provide thought provoking
correlations and warrant further investigation on the
adjustment of measured values according to baseline
variables such and body size and composition. It is inter-
esting that here as well as in another recent study [47], the
strongest correlations between measured parameters and
‘‘outcomes of sarcopenia’’ were not always the same in
men and women. In the study by Scott and colleagues [47],
the baseline data of an adult cohort (n = 1100) were
analysed using various definitions of sarcopenia and the
results correlated with the 5-year falls risk scores. The
strongest correlations were men classified with sarcopenia
according to anthropometric definitions (ALM corrected
for height, weight or a residual), and women classified with
sarcopenia according to performance-based definitions
(HGS and lower-limb strength). Thus, there may be dif-
ferent processes in ageing between men and women that
should be taken into account.
Comparing the rates of positive identifications obtained
by the FNIH-SP threshold with previously suggested
thresholds, suggests that the newer thresholds might be too
severe. For example, applying the proposed HGS and
ALMBMI, thresholds to the FNIH-SP pooled population
resulted in just 1.3 % of the men and 2.3 % of the women
being classified as ‘‘sarcopenic’’ and if the gait speed cri-
terion was included then the yield was even lower [44].
Using the EWGSOP criteria on the same pooled dataset,
the group sizes were 5.3 and 13.3 %, for men and women,
respectively [44]. Testing the various thresholds suggested
by EWGSOP on a Belgian cohort aged 65 years or more,
Beaudart and colleagues found that the prevalence of sar-
copenia (men and women) varied from 9 to 18 % [48].
When the analysis was carried out by age group, a higher
incidence of sarcopenia was evidence with increasing age.
Bischoff-Ferrari and colleagues [49] have also explored the
consequences of using different definitions of sarcopenia to
prospectively identify community-dwelling seniors who
have a greater risk of falling, with the result that the
strongest association was found using thresholds based on
ALM corrected for height squared, although the EWGSOP
definition was also strongly predictive. Clearly the choice
of thresholds will significantly affect the size of the
affected population, but the important data that are missing,
concern the overall risk in the observed sample of indi-
viduals in terms of severe outcomes (major mobility
impairment, falls, fracture, nursing home admissions,
mortality) over the short- and long-term. Indeed, even if
more and more data suggest that sarcopenia is associated
with poor health outcomes, the methodology including the
definition of sarcopenia differs widely between studies.
More work is needed to characterise the hazard rates in a
group of ‘‘sarcopenic’’ individuals.
Target populations and study design for regulatory
studies in the treatment of sarcopenia
The selection of patients for clinical research in the context
of regulatory filing depends on the aims of the project and
its stage in the development process (illustrated in sup-
plementary data, Fig. 1). At early stages of development,
the selection of the research population is more restrictive
to reduce the possibility of confounding, but as the
development process advances and different subgroups
with specific comorbidities are integrated, then the popu-
lation should broaden. Considerations for target popula-
tions for pharmaceutical trials in sarcopenia have been
made previously [50, 51] and most recently by Vellas and
colleagues [52]. It might also be added that prevention of
sarcopenia in high-risk ‘‘pre-sarcopenic’’ individuals could
be an achievable long-term goal. The EWGSOP suggested
that a pre-sarcopenia stage could be characterised by the
existence of low muscle mass alone. The concept of tar-
geting such a population to slow or prevent the progression
to sarcopenia might be considered as being similar to the
recently completed LIFE study [53] in which older persons
with a sedentary lifestyle and at high risk of mobility dis-
ability (Short Physical Performance Battery [SPPB] score
\10) but able to walk 400 m in under 15 min, were ran-
domised to an exercise programme compared with a health
education programme. Although the inclusion criteria were
quite different from that suggested by EWGSOP the end-
point of major mobility disability after a planned
31 months of follow-up appears pertinent.
The target population for the treatment of sarcopenia (or
pre-sarcopenia) should be men and women aged 65 years
or more [2, 30]. In the screening (diagnostic) process to
recruit patients we advocate the use the EWGSOP criteria.
The assessment of baseline parameters in the selected
population of older individuals should as thorough as
possible so that individual risk status can be assessed, as
well as providing information on other more exploratory
variables (examples provided in supplementary data
Table 1). For any drug development plan, it will be
important to engage in dialogue with regulators during its
Aging Clin Exp Res (2016) 28:47–58 51
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design to validate recruitment decisions and exclusion
criteria.
Phase II
In a phase II programme (about 300 individuals),
exploratory and proof of concept studies are followed by
dose-ranging and short-term efficacy studies. The study
population must be relatively homogeneous with the
exclusion of a range of comorbid conditions to reduce
confounding of the diagnosis or efficacy assessment (e.g.
major endocrine, pulmonary, cardiac neurological or renal
conditions, as well as chronic inflammatory rheumatic
conditions).
A recently published international phase II study in
sarcopenia, which was designed to test the effects of the
selective androgen receptor modulator [54], selected
women of 65 years old or more, with low ALM (ALM/
height2 versus reference), self-reported mobility disability
and an SPPB score between 4 and 9. The exclusion criteria
included an extensive list of comorbidities (Supplementary
data, exclusion criteria). The research team reported a
randomisation rate of 29 % of those screened (170 out of
592).
Phase III
The phase III study population should be a logical con-
tinuation of the phase II programme so as to provide
convincing data on the benefit–risk balance of the study
drug or intervention in the intended target population.
There should be no upper age limit for the included pop-
ulation [55]. Special subpopulations should be considered,
for example persons with previous hip fracture, or con-
comitant condition or those in particular settings (e.g.
nursing home or acute care).
Study design
The placebo-controlled, parallel arm, double-blind trial is
the mainstay of regulatory study design and is suit-
able here. A stable baseline should be ensured with a rel-
atively long run-in phase before treatment start (e.g.
4–6 weeks) during which activity diaries could be moni-
tored and any dietary failings or anaemia corrected [56,
57]. Studies should, as much as possible, have similar time
points for assessment (e.g. 1 month, 3 months, 6 months,
1 year) so that comparisons between studies, and thus data
pooling, or meta-analyses, are facilitated. For studies in
pre-sarcopenic patients that aim to slow or prevention the
progression to sarcopenia, longer follow-up durations will
probably be necessary.
Outcome measures
The primary endpoints in the exploratory and dose-ranging
stages of a phase II programme are likely to be biological
and/or pharmacodynamic parameters. The European Drug
Agency (EMA) has emphasized that it is important to
perform modelling of population pharmacokinetics as well
as specific pharmacokinetic studies in the very elderly. As
the development proceeds to short-term efficacy studies,
then the choice of efficacy measures needs to be taken. The
relevant functional outcome measures in this phase are gait
speed, lower leg strength and possibly other more func-
tional tests such as SPPB [58] and Timed Up and Go
(TUG) [59], which have their minimal clinically meaning
differences already established.
A phase III pivotal study needs to show substantial
evidence that a drug will have the desired effect in the
proposed labelling; the primary endpoint should be a direct
measure of either: improved survival; a benefit
detectable by the patient (e.g. improvement in functional
capacity); or a reduction in the risk of developing a con-
dition (e.g. mobility disability), or disease complication
that is itself apparent to the patient and undesirable. How
any improvement in physical functioning might lead to
reduced costs for healthcare systems will be important to
support the submission [60].
It is challenging to identify a single clinical endpoint
that is sufficiently robust and therefore more that one
measure should be selected (although the question of a co-
primary endpoint is debatable). Possible outcome measures
are listed in Table 1. Longer duration exercise tests have a
stronger case for being a meaningful function outcome and
are highly relevant to older patients for whom crossing the
road may be a risky enterprise [35]. There are two well-
known walking protocols of similar discriminatory effi-
cacy: the 6-min walk test and the 400 m walk test. The
result of the 6-min walk test is the total distance walked
over 6-min has proved popular in studies of cardiac reha-
bilitation. The result of the 400 m walk test [61] measures
the time taken to walk that distance and has a high test–
retest reliability [62]. It can also be used as a binary out-
come (yes/no result) whether the person can complete the
test within 15 min or not. Stair climbing can be discrimi-
natory and particularly when ‘‘loaded’’, i.e. carrying a bag
in each hand with a combined weight of 20–25 % of body
weight [63]. Tests of thigh muscle strength (knee exten-
sion) have also shown their value in research [64, 65] but
specialised equipment is required. Muscle fatigue is an
important aspect of muscle performance and various
methods exist to measure it [66–68], but no clear choice
stands out at this stage. Any measure of muscle perfor-
mance must clearly take into account the capacity of the
52 Aging Clin Exp Res (2016) 28:47–58
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sample population to perform it, since some can be quite
challenging. Improvement under treatment using shorter
tests such measures as gait speed, SPPB and TUG test will
probably only be considered as supporting evidence, since
these surrogates have no proven direct relationship to
clinical benefit.
The assessment of falls has been suggested as a possible
outcome in sarcopenia studies. Up until now this type of
measure has relied heavily on the patient recording in a
diary the occurrence of falls and therefore of uncertain
reliability. Recently, however, with the development of
mobile electronic devices [69], smart wearable sensors and
motion detectors are becoming much cheaper and more
reliable for research purposes [70], potentially allowing a
more objective assessment.
For complete assessment of the benefits of any intervention
it is important to provide evidence of the impact in terms of
health status and quality of life and it will be essential to place
any clinical trial data in the context of a comprehensive global
assessment in older peoplewith chronic illness [71]. There are a
number of well-known patient-reported outcome (PRO)
instruments available, however, as reported previously [8] the
validity of many of these PRO instruments is poorly docu-
mented in older populations. Probably the most suitable in-
strument at the present time is the SF-36 [72], since it
adequately covers the three key domains (physical/occupa-
tional function, social health/integration, and mental health/
psychological state), is not too onerous to complete, is well
known and has proved suitable in more than one sarcopenic/
frail cohort [73, 74]. The EQ-5D [75] has also been used as a
PRO instrument in sarcopenia and under-nutrition research.
These remain, however, ‘‘generic’’ measures and as such may
be relatively insensitive to some perceived changes [8].
A core outcome set
The selection of a core outcome set to be used in all
clinical trials of sarcopenia would be an important goal
of a clinical guideline. Even if the main endpoints might
vary in different studies, having a core outcome set
would enhance trial comparison and therefore improve
the evidence base, as has been shown for rheumatolog-
ical diseases [76, 77]. Recently, the Core Outcomes
Measure in Effectiveness Trials (COMET) initiative [78]
was established to provide a database of such outcome
sets and help their development and utilisation. Outcome
measures in rheumatology (OMERACT), has developed
a tool, ‘‘filter 2.0’’, which outlines the intellectual pro-
cess of deciding first what to measure (domains), and
then how to measure it (instruments) [79]. This tool
suggests that three core areas that should always be
addressed in a core set: death, life impact and patho-
physiological manifestations of the disease; a fourth
area, resource use, is strongly recommended. The
resulting sets of domains and measurement instruments
should then pass through a consensus selection process.
Figure 1 illustrates this process with reference to
sarcopenia.
The impact area ‘death’ is invariant in the filter and an
important outcome measure. Adverse events are also
important and researchers should decide if specific adverse
events need to be monitored as part of the core set. ‘Life
impact’ includes assessments of mobility/disability which,
for sarcopenia, would include the strong endpoints of falls
and fractures, reduced mobility, frailty onset (e.g. Fried
criteria [80], Instrumental Activities of Daily Living, (Ba-
sic Activities of Daily Living [81]), as well as PRO
instruments relating to quality of life. ‘Resource use’ is a
core area of interest in later stage development. The
domains are fairly self-explanatory and the relevant metric
is monetary units [although unitary use of health care
resources (specialist care, home care, admission to nursing
home) could be considered]. It should be added that an
important (and growing) proportion of older people are
employed in some sense or another, notably in voluntary
work (e.g. in libraries, caring for partners or family
members). ‘Pathophysiological manifestations of sarcope-
nia’ includes direct measures of muscle function and
structure (see Fig. 1).
Table 1 Some outcome measures proposed for phase III regulatory studies
Outcome measure Test
Falls Incident falls or perhaps incident recurrent falls (i.e. C2 falls); but unless the person is fitted with an accelerometer this is
a patient-reported outcome
Major mobility
disability
Incapacity to complete 400 m walk test within 15 min (i.e.\0.45 m/s)
ADL disability Activities of daily living (ADL)
Patient-reported
outcomes
The 36-item short-form (SF-36) of the Medical Outcomes Study (a generic QOL tool)
EQ-5D (a generic QOL tool)
A specific age-related tool (see reference [8])
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A strong recommendation of ESCEO is therefore that a
core set be developed for use in sarcopenia, i.e. the
selection of at least one applicable instrument for the
assessment of each core domain.
Discussion
Healthy ageing is a major goal of both European and
international initiatives [82, 83]; with the increasing lifes-
pan in western populations, it is becoming more and more
important to prevent disability for as long as possible.
Important advances have been made in defining sarcopenia,
particularly with the consensus definitions of 2010 and the
recent input from the FNIH Sarcopenia Project and there is
now a ‘‘broad support for the existence of a clinically
important condition of low muscle mass and weakness’’
[30]. The evidence suggests that sarcopenia is a treat-
able condition. While one solution might be to prescribe an
exercise programme, many older individuals lack the
necessary physical and mental energy to pursue it or may
be physically impaired and so unable to participate. For
these individuals a pharmaceutical product could be of help
and indeed numerous agents currently under assessment for
the treatment of sarcopenia, including testosterone, dehy-
droepiandrosterone, oestrogen, growth hormone, ghrelin,
angiotensin converting enzyme inhibitor, eicosapentaenoic
acid and ryanodine receptor modulators [6]. Other thera-
pies include various oral nutritional supplements (proteins,
amino acids, vitamin D, etc.).
The public health problem associated with sarcopenia is
likely to be substantial [84] but, because of the uncertainty in
the diagnosis of sarcopenia its prevalence and epidemiology,
the size of the problem is far from clear. In a much quoted
paper from 2004, the costs attributable to sarcopenia (with a
diagnosis based on muscle mass index only) using risk
estimates of progression to disability and estimations of the
cost burden by disability scoring, were estimated at $18.5
billion per year in the USA (range $11.8–26.2 billion) [85].
For comparison the attributable costs of osteoporosis
according to the American National Osteoporosis Founda-
tion, is $13.8 billion a year, affecting approximately 2 mil-
lion Americans (80 % of them women).
As well as preventative physical activity programmes,
oral supplements and perhaps pharmaceutical interven-
tions, older adults need to be better educated in the
importance of healthy nutrition and body weight. Adults
need to know the importance of ‘‘sufficient’’ muscle mass
Fig. 1 The application of the OMERACT filter 2.0 for the definition of core outcomes for sarcopenia. ICF International Classification of
Functioning, Disability and Health framework of the World Health Organisation
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and muscle function and the dangers associated with
increase fat mass; to understand that if the ratio of fat and
muscle increases in favour of fat, they risk not being able to
get up from a chair or walk safely in old age, and having a
high chance of developing other problematic chronic con-
ditions. Effective strategies for pre-sarcopenia and sar-
copenia will need to combine, nutritional support and
education to reduce sedentary behaviour and encourage
exercise. The benefits of pharmaceutical intervention in
resistant cases will then have to be weighed against the
risks in a population likely to be poly-medicated. The
development and evaluation of complex interventions (or
‘‘multifactorial interdisciplinary’’ interventions) will be
challenging [86].
A research agenda
There are still numerous gaps in our knowledge, particu-
larly concerning risk assessment. It would be instructive to
build risk models similar to those for osteoporosis, starting
with the person’s age, sarcopenia-related risk factors and
other risk factors and assess the outcome for this individual
over time. Although it is argued that age may have little
relevance in a diagnosis of frailty [87], it remains a rea-
sonable approximation to biological age and its associated
hormonal changes. Age is also a good predictor of osteo-
porotic fracture risk [88].
The value of indexing threshold values for sarcopenia
measures and outcomes needs to be further investigated, as
does the need for sex-dependent values for gait speed. Such
an evaluation would best be achieved using a risk-based
analysis for one of the discussed strong clinical endpoints.
A consensus core outcome set would bring standard-
ization and comparability to research in sarcopenia and
therefore would help improve the evidence base for health
care [77]. A selection of the proposed outcomes and the
measurement techniques is required and some issues could
be resolved by launching a consultation with a Delphi type
voting process.
It is very important that thresholds should be selected
using the best evidence so they can be widely accepted. In
the light of new evidence, they can be modified; as pointed
out by Studenski and colleagues [30], the currently
accepted threshold values for blood pressure, blood sugar
concentration, or cholesterol levels, used respectively, to
diagnose hypertension, diabetes and hyperlipidemia, were
all selected empirically from a continuous graded rela-
tionship of risk of serious adverse events and all have
evolved over time.
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